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ABSTRACT
Introduction: Although a large recent trial had
shown improved cardiovascular outcomes of
diabetic patients on sodium glucose
co-transporter-2 (SGLT-2) inhibitors, the
influence of gender differences on such
outcomes is not known. Thus, we aimed to
assess the impact of gender on such outcomes
in the patients with type 2 diabetes mellitus
receiving SGLT-2 inhibitors.
Methods: A search of electronic databases was
conducted for all randomized trials comparing
SGLT-2 inhibitors with placebo in patients with
diabetes mellitus. Primary outcomes were
all-cause mortality and cardiovascular
mortality. Random effects meta-regression was
conducted using the percentage of women
included in the SGLT-2 inhibitor arm of each
trial with a P value of \0.1 for statistical
significance.
Results: A total of 22,256 patients from 26 trials
were included. The overall odds ratio (OR) of
all-cause mortality [OR = 0.72, 95% confidence
interval (CI) 0.60–0.86, P\0.001, I2 = 0%], and
cardiovascular mortality (OR = 0.67, 95% CI
0.53–0.84, P = 0.001, I2 = 23%) were lower
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with SGLT-2 inhibitors. Meta-regression
suggested a possible incremental increase in
the OR for all-cause mortality and
cardiovascular mortality as the percentage of
women in the SGLT-2 inhibitor arm increased
(P = 0.07 and 0.08, respectively).
Conclusion: Gender might influence the
cardiovascular benefits observed with SGLT-2
inhibitors in patients with type 2 diabetes
mellitus.
Keywords: Diabetes mellitus; Incretins;
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INTRODUCTION
Sodium glucose co-transporter-2 (SGLT-2)
inhibitors are recommended as mono- or
combined therapy in the management of type
2 diabetes. A recent large multi-center
randomized trial showed reduction in the
cardiovascular adverse outcomes with
empagliflozin, compared with placebo [1]. On
subgroup analysis by gender, the risk of all-cause
mortality, and cardiovascular mortality appeared
to be reduced only in men [1]. In addition, some
studies had suggested possible gender differences
in the risk of cardiovascular events in patients
with type 2 diabetes [2, 3]. Therefore, we aimed
to explore the impact of gender on the
cardiovascular benefits observed with SGLT-2
inhibitors in type 2 diabetes.
METHODS
A detailed explanation of the methods was
discussed in a prior publication [4]. A
comprehensive search of the MEDLINE,
CENTRAL, Web of Science, Embase and
Clinialtrials.gov databases was conducted
without language restrictions from inception
until July 2016 for randomized trials that
compared SGLT-2 inhibitors with placebo in
patients with type 2 diabetes, and reported
cardiovascular outcomes. The outcomes of
interest were all-cause mortality, and
cardiovascular mortality. Two parallel teams of
reviewers independently collected the data of
interest. Any inconsistencies were resolved by
consensus. A weighted estimate of the overall
percentage of women in the SGLT-2 inhibitors
arm was calculated with 95% confidence
interval (CI). Intention to treat summary odds
ratios (OR) were calculated with P values of
\0.05 and 95% CI for statistical significance by
the Peto method, given the paucity of events.
Heterogeneity was assessed by I2 statistic test,
where values \25%, 25–50% and [50% were
corresponding to low, moderate and high
degrees of heterogeneity, respectively. Random
effects meta-regression was conducted to
explore the gender effect using the percentage
of women included in the SGLT-2 inhibitor arm
of each trial with a P value of\0.1 for statistical
significance. Trials with zero events in either
arm were excluded from the meta-regression
analysis. A subgroup analysis was also
performed according to the percentage of
females in the treatment arm of each trial,
with a cut level of 50%. All analyses were
conducted using STATA version 14 (STATA
Corporation; College Station, Texas, USA).
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
A total of 22,256 patients from 26 trials were
included. The overall percentage of women in
SGLT-2 inhibitors arm was 58% (95% CI
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54–62%). The overall incidence of all-cause
mortality (OR = 0.72, 95% CI 0.60-0.86,
P\0.001, I2 = 0%), and cardiovascular
mortality (OR = 0.67, 95% CI 0.53–0.84,
P = 0.001, I2 = 23%) were lower with SGLT-2
inhibitors compared with placebo.
Meta-regression analysis for trials reporting at
least one event in either arm suggested a
possible incremental increase in the OR for
all-cause mortality and cardiovascular mortality
as the percentage of women in the SGLT-2
inhibitor arm increased (P = 0.07 and 0.08,
respectively) (Fig. 1). A subgroup analysis
according to the percentage of females
included in each trial illustrated a significant
reduction in all-cause mortality when the
percentage of females was B50% (OR = 0.70,
95% CI 0.60–0.84, P\0.001, I2 = 0%) but not
when it was [50% (OR = 1.07, 95% CI
0.40–2.87, P = 0.90, I2 = 0%). The same was
true for cardiovascular mortality (OR = 0.66,
95% CI 0.53–0.81, P\0.001, I2 = 0% versus
OR = 1.72, 95% CI 0.37–8.06, P = 0.49,
I2 = 0%, respectively).
DISCUSSION
This meta-regression and subgroup analysis of
26 randomized trials demonstrated a possible
gender influence on the cardiovascular benefits
observed with SGLT-2 inhibitors, with an
incremental decrement in benefit as the
percentage of women included in the SGLT-2
inhibitor arm was higher. Although EMPA-REG
OUTCOME trial showed a significant reduction
in adverse cardiovascular outcomes with
empagliflozin, approximately 70% of the
patients were men [1]. A subgroup analysis of
EMPA-REG OUTCOME trial suggested that
there might be possible gender differences:
hazard ratio (HR) 0.62, 95% CI 0.50–0.77 in
men, versus HR 0.91, 95% CI 0.63–1.32 in
women for all-cause mortality [5]. These
speculations are further supported by our
analysis. Experimental animal studies had
suggested that the expression of SGLT-2
co-transported protein and SGLT-2 inhibitors
metabolism are different in males compared
with females [6]; however, these findings were
not supported in human studies [7]. Some
studies have shown that cardiovascular
morbidity and mortality are more pronounced
in diabetic women compared with men, despite
adherence to the guideline recommended
therapies, as a result of the higher risk factor
Fig. 1 Random effect meta-regression analysis of all-cause
mortality (a) and cardiovascular mortality (b) odds ratio
with SGLT-2 inhibitors according to the mean percentage
of females in each trial. CI conﬁdence interval, SGLT-2
sodium glucose co-transporter-2. * A total of 26 trials
reported all-cause mortality and 14 trials reported
cardiovascular mortality
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profile and increased atherogenic potential in
women [2, 3].
CONCLUSION
In conclusion, gender might influence the
cardiovascular benefits observed with SGLT-2
inhibitors in patients with type 2 DM. Future
randomized trials are required to confirm these
findings.
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